Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than comprehensive financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs. On April 30, 2010, an increase in the notional allocation of Ordinary share ADRs was recorded at a price of $37.29 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items beyond the specific transaction notification. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 30, 2010 (Notification date: May 4, 2010).
- Subject: Ms D Connelly.
- Instrument: GSK Ordinary share ADRs within the US Retirement Savings Plan.
- Price: $37.29 per ADR.
- Nature of Event: Increase in notional allocation following a re-valuation of the cash element.